Mapping of F. tularensis T cell epitopes in Mice

小鼠 T 细胞表位定位

基本信息

项目摘要

DESCRIPTION (provided by applicant): Inhalation of the intracellular gram-negative bacterium Francisella tularensis is highly fatal in humans. Since F. tularensis can be easily weaponized into an aerosolized form, it is considered to be one of the most important potential biowarfare agents. The virulence determinants and protective antigens of F. tularensis have been poorly characterized. To date, the F. tularensis live vaccine strain (LVS), which is derived from F. tularensis subspecies holarctica (type B), has demonstrated varying degrees of protection in humans. However, the protective antigens expressed by the LVS strain have yet to be characterized, and attenuated LVS is unlikely to pass approval for current safety standards for vaccines. Therefore, development of a licensed subunit vaccine, which is currently not available, is of utmost importance. It is our long-term goal to identify candidate T cell epitopes of F. tularensis in "humanized" HLA-DR transgenic mice that can be used to develop subunit vaccines to induce protective immunity in humans. The specific hypothesis underlying this application is that protective T cell epitopes of F. tularensis can be identified in "humanized" HLA-DR transgenic mice that are also processed and presented by human APCs and could be used for the design of a subunit vaccine. We base this hypothesis on the following observations: First, protection to Francisella infection appears to be critically dependent on specific T cell immunity and T cell-derived production of IFNg. Second, vigorous T cell proliferation and cytokine production was detected in HLA-DR4 tg mice upon vaccination with LVS. Third, T cell epitopes of self- and microbial antigens identified in the HLA-DR4 transgenic mice are relevant to humans. We base this assumption on our preliminary data showing that T cell epitopes characterized in "humanized" HLA-DR4 transgenic mice are processed and presented by human HLA-DR4+ APCs. Thus, overall, we believe that the HLA transgenic animals provide a novel tool and model to identify T cell determinants of F. tularensis that have potential use for the development of vaccines for humans. We will test this hypothesis with the following specific aims: Specifically, we will (1) characterize the F. tularensis proteins that induce protective T cell immunity in HLA-DR4 (DRB1*0401) ransgenic mice. (2) Identify protective T cell peptide epitopes in the HLA-DR tg mice. (3) Examine whether epitopes presented by the HLA-DR tg mice are also presented by human APCs.
描述(由申请人提供):吸入细胞内革兰氏阴性菌土拉菌弗朗西斯菌对人类是高度致命的。因为土拉菌很容易被武器化

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bernard Pragash Arulanandam其他文献

Bernard Pragash Arulanandam的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Bernard Pragash Arulanandam', 18)}}的其他基金

Thioredoxin mediated Acinetobacter baumannii colonization in the GI tract
硫氧还蛋白介导的鲍曼不动杆菌在胃肠道中的定植
  • 批准号:
    9092838
  • 财政年份:
    2016
  • 资助金额:
    $ 22.01万
  • 项目类别:
The Contribution of MicroRNA-182 in Genital Chlamydia trachomatis Infection
MicroRNA-182在生殖器沙眼衣原体感染中的作用
  • 批准号:
    9318447
  • 财政年份:
    2016
  • 资助金额:
    $ 22.01万
  • 项目类别:
Evaluation of CPAF Mediated Anti-Chlamydial Immunity in the Guinea Pig
CPAF 介导的豚鼠抗衣原体免疫的评价
  • 批准号:
    8030633
  • 财政年份:
    2011
  • 资助金额:
    $ 22.01万
  • 项目类别:
Evaluation of CPAF Mediated Anti-Chlamydial Immunity in the Guinea Pig
CPAF 介导的豚鼠抗衣原体免疫的评价
  • 批准号:
    8306095
  • 财政年份:
    2011
  • 资助金额:
    $ 22.01万
  • 项目类别:
CPAF induced CD4+ T cell mediated immunity against Chlamydia
CPAF 诱导 CD4 T 细胞介导的针对衣原体的免疫
  • 批准号:
    8128112
  • 财政年份:
    2010
  • 资助金额:
    $ 22.01万
  • 项目类别:
CPAF induced CD4+ T cell mediated immunity against Chlamydia
CPAF 诱导 CD4 T 细胞介导的针对衣原体的免疫
  • 批准号:
    8197433
  • 财政年份:
    2008
  • 资助金额:
    $ 22.01万
  • 项目类别:
CPAF induced CD4+ T cell mediated immunity against Chlamydia
CPAF 诱导 CD4 T 细胞介导的针对衣原体的免疫
  • 批准号:
    7993092
  • 财政年份:
    2008
  • 资助金额:
    $ 22.01万
  • 项目类别:
CPAF induced CD4+ T cell mediated immunity against Chlamydia
CPAF 诱导 CD4 T 细胞介导的针对衣原体的免疫
  • 批准号:
    7742663
  • 财政年份:
    2008
  • 资助金额:
    $ 22.01万
  • 项目类别:
CPAF induced CD4+ T cell mediated immunity against Chlamydia
CPAF 诱导 CD4 T 细胞介导的针对衣原体的免疫
  • 批准号:
    8389670
  • 财政年份:
    2008
  • 资助金额:
    $ 22.01万
  • 项目类别:
CPAF induced CD4+ T cell mediated immunity against Chlamydia
CPAF 诱导 CD4 T 细胞介导的针对衣原体的免疫
  • 批准号:
    7579715
  • 财政年份:
    2008
  • 资助金额:
    $ 22.01万
  • 项目类别:

相似海外基金

Modulation of T lymphocyte Activation by ß2-Adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    RGPIN-2019-06980
  • 财政年份:
    2022
  • 资助金额:
    $ 22.01万
  • 项目类别:
    Discovery Grants Program - Individual
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
  • 批准号:
    10581488
  • 财政年份:
    2022
  • 资助金额:
    $ 22.01万
  • 项目类别:
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574979-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 22.01万
  • 项目类别:
    University Undergraduate Student Research Awards
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
  • 批准号:
    10332251
  • 财政年份:
    2022
  • 资助金额:
    $ 22.01万
  • 项目类别:
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574984-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 22.01万
  • 项目类别:
    University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574985-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 22.01万
  • 项目类别:
    University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
  • 批准号:
    574978-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 22.01万
  • 项目类别:
    University Undergraduate Student Research Awards
Investigating the cell-based activity of a new class of cytotoxic T-lymphocyte antigen-4 (CTLA-4) small molecule inhibitors
研究一类新型细胞毒性 T 淋巴细胞抗原 4 (CTLA-4) 小分子抑制剂的细胞活性
  • 批准号:
    444149
  • 财政年份:
    2021
  • 资助金额:
    $ 22.01万
  • 项目类别:
    Operating Grants
Novel pathways in T lymphocyte differentiation and function
T 淋巴细胞分化和功能的新途径
  • 批准号:
    RGPIN-2015-05491
  • 财政年份:
    2021
  • 资助金额:
    $ 22.01万
  • 项目类别:
    Discovery Grants Program - Individual
Modulation of T lymphocyte Activation by ß2-Adrenergic Receptor Signalling Pathways
通过 α2-肾上腺素能受体信号通路调节 T 淋巴细胞激活
  • 批准号:
    RGPIN-2019-06980
  • 财政年份:
    2021
  • 资助金额:
    $ 22.01万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了